SA
ABPWW logo
Abpro Holdings Inc(ABPWW)
Last print 8 weeks agoAbout this dataData status
$0.00▲0.00 (0.00%)Stale · 8 weeks oldEarnings · Dec 2
Extended:$0.01+0.01 (+447.62%)· 9:53 AM ET

Nasdaq, Russell 2000 below the 200-day average · S&P 500 below the 50-day average (VIX 24.6)

Overview →

Abpro Holdings Inc focuses on developing monoclonal antibodies for therapeutic applications, primarily targeting cancer and autoimmune diseases. The company differentiates itself through its proprietary AbCellera platform, which enables rapid discovery and optimization of antibody candidates, positioning it well in the competitive biotech landscape.

HealthcareBiotechnologylow - The company has high fixed costs associated with R&D and technology development, leading to low operating leverage.

Business Overview

01Monoclonal antibody development services - 100%

Abpro generates revenue by partnering with pharmaceutical companies to develop monoclonal antibodies, leveraging its proprietary technology to streamline the discovery process. The company benefits from milestone payments and royalties on successful products, providing a diversified income stream.

What Moves the Stock

Success in clinical trials for lead antibody candidates

Partnership announcements with major pharmaceutical companies

Regulatory approvals for new therapies

Market adoption rates of developed therapies

Watch on Earnings
Clinical trial progress updatesPartnership revenue milestonesR&D expense management

Risk Factors

Regulatory changes affecting drug approval processes

Technological disruption in antibody development

Emergence of new biotech firms with similar technologies

Established pharmaceutical companies developing in-house capabilities

Negative cash flow impacting operational sustainability

Limited financial resources for extensive R&D

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - The biotech sector is somewhat insulated from economic cycles, but funding and investment can be affected by broader economic conditions.

Interest Rates

Higher interest rates could increase the cost of capital for R&D funding, potentially impacting Abpro's ability to finance its projects and partnerships.

Credit

minimal - The company has a negative debt/equity ratio, indicating low reliance on debt financing.

Live Conditions
S&P 500 FuturesDow Jones FuturesRussell 2000 Futures

Profile

growth - Investors looking for high-risk, high-reward opportunities in biotech.

high - The stock has shown significant volatility, particularly given its recent performance.

Key Metrics to Watch
Clinical trial success rates
Partnership revenue growth
R&D expenditure as a percentage of revenue
Regulatory approval timelines
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.